Artivion Inc.

Company Overview

Medical device manufacturer Artivion was established in 1984 as CryoLife Inc. It changed its name to Artivion in 2022 as Artivion Inc. It is a leader in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Aortic arch stent grafts include our E-vita Open NEO, E-vita Open Plus, the Ascyrus Medical Dissection Stent (“AMDS”) hybrid prosthesis, the NEXUS endovascular stent graft system (“NEXUS”), and E-vita Thoracic 3G products.

Abdominal stent grafts include its E-xtra Design Engineering, E-nside, E-tegra, E-ventus BX, and E-liac products. Surgical sealants include BioGlue Surgical Adhesive (“BioGlue”) products. In addition to these four major product families, it sells or distributes PhotoFix bovine surgical patches, CardioGenesis cardiac laser therapy, and PerClot hemostatic powder (prior to the sale to a subsidiary of Baxter International Inc.).

Artivion has over 1,600 employees worldwide with sales representation in over 100 countries. The company has manufacturing facilities located in Atlanta, Ga.; Austin, Texas; and Hechingen, Germany. Additionally, it has sales and distribution offices in various countries throughout Europe, Asia, and South America.

Financial Highlights (FY 2023)

Company's Business Segments

• Products : Aortic Stent Grafts, On-X, Surgical Sealants, Others
• Preservation Services : Services revenue generated from the preservation of cardiac and vascular implantable human tissues.